|
|
Basilea Pharmaceutica Ltd. is a biopharmaceutical company headquartered in Basel, Switzerland, listed on the SWX Swiss Exchange (SWX:BSLN). The company is focused on the discovery, development and commercialization of innovative medicines to satisfy high medical and patient needs in the hospital and specialty pharmaceutical setting.
Basilea has a fully integrated R&D organization and is currently building its sales and marketing organization in the U.S., Canada and major European markets. The company owns a broad and balanced late-stage product portfolio including novel treatments for resistant bacterial infections, systemic fungal infections, and severe skin diseases. The product pipeline comprises two drug candidates in pre-registration, one in clinical phase III as well as substantial innovative early-stage programs.
Ceftobiprole, a new anti-MRSA broad-spectrum antibiotic, receives its first marketing authorization by Health Canada Basilea Pharmaceutica Ltd. announces that ceftobiprole (ZEFTERA™), the first-in-class anti-MRSA broad-spectrum cephalosporin, has obtained regulatory approval from Health Canada authorizing the marketing of ceftobiprole for the treatment of complicated skin and soft tissue infections including diabetic foot infections. In addition, Basilea announces further organizational changes in preparation of product commercialization. more...
|
Ceftobiprole shows high cure rates in patients hospitalized with community-acquired pneumonia Basilea Pharmaceutica Ltd. (SWX:BSLN) highlights the presentation of positive phase III results on ceftobiprole in the treatment of community-acquired pneumonia (CAP) requiring hospitalization at the International Conference of the American Thoracic Society (ATS). The detailed analysis of previously announced top line results demonstrate high cure rates in patients at risk for poor outcomes. more...
|
Canadian regulatory authority has accepted New Drug Submission for alitretinoin for review Basilea Pharmaceutica Ltd. (SWX:BSLN) announces that the Therapeutic Products Directorate (TPD) of Health Canada has accepted for review the New Drug Submission of oral alitretinoin for the treatment of severe refractory chronic hand eczema. more...
|
New scientific data on ceftobiprole and isavuconazole will be presented at ECCMID Basilea Pharmaceutica Ltd. highlighted today that new research and preclinical data on two late-stage product candidates ceftobiprole and isavuconazole will be presented at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Poster and oral presentations reflect the advanced stage of development of the broad-spectrum anti-MRSA antibiotic ceftobiprole. Additionally, publications on isavuconazole present further research results confirming the differentiated profile of the compound. more...
|
|
|
